Race Oncology Secures IND Approval for Cancer Drug Candidate in South Korea; Shares Up 8%

MT Newswires Live

Sep 24

Race Oncology (ASX:RAC) said South Korea's Ministry of Food and Drug Safety (MFDS) approved the investigational new drug application (IND) to evaluate the safety, tolerability, and pharmacokinetics of the company's cancer drug candidate RC220 in combination with doxorubicin in solid tumor patients, subject to minor updates of the trial protocol, according to a Wednesday Australian bourse filing.

The approval has been granted following a review of the chemistry, manufacturing, and controls, as well as nonclinical and clinical data packages for RC220, the filing added.

The company said the approval enables patient recruitment at four sites in South Korea, with local ethics approval received.

The company's shares rose 8% in recent Wednesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569740112"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569740112\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569740112?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 08:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569740112","market":"fut","top_or_hot":-1,"title":"Race Oncology Secures IND Approval for Cancer Drug Candidate in South Korea; Shares Up 8%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RAC.AU\">Race Oncology</a> (ASX:RAC) said South Korea's Ministry of Food and Drug Safety (MFDS) approved the investigational new drug application (IND) to evaluate the safety, tolerability, and pharmacokinetics of the company's cancer drug candidate RC220 in combination with doxorubicin in solid tumor patients, subject to minor updates of the trial protocol, according to a Wednesday Australian bourse filing.</p><p>The approval has been granted following a review of the chemistry, manufacturing, and controls, as well as nonclinical and clinical data packages for RC220, the filing added.</p><p>The company said the approval enables patient recruitment at four sites in South Korea, with local ethics approval received.</p><p>The company's shares rose 8% in recent Wednesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Race Oncology Secures IND Approval for Cancer Drug Candidate in South Korea; Shares Up 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRace Oncology Secures IND Approval for Cancer Drug Candidate in South Korea; Shares Up 8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-24 08:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RAC.AU\">Race Oncology</a> (ASX:RAC) said South Korea's Ministry of Food and Drug Safety (MFDS) approved the investigational new drug application (IND) to evaluate the safety, tolerability, and pharmacokinetics of the company's cancer drug candidate RC220 in combination with doxorubicin in solid tumor patients, subject to minor updates of the trial protocol, according to a Wednesday Australian bourse filing.</p><p>The approval has been granted following a review of the chemistry, manufacturing, and controls, as well as nonclinical and clinical data packages for RC220, the filing added.</p><p>The company said the approval enables patient recruitment at four sites in South Korea, with local ethics approval received.</p><p>The company's shares rose 8% in recent Wednesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7095","symbol_name":"多种金属与采矿","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2569740112","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569740112","pubTimestamp":1758674653,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Race Oncology  said South Korea's Ministry of Food and Drug Safety  approved the investigational new drug application  to evaluate the safety, tolerability, and pharmacokinetics of the company's cancer drug candidate RC220 in combination with doxorubicin in solid tumor patients, subject to minor updates of the trial protocol, according to a Wednesday Australian bourse filing.The approval has been granted following a review of the chemistry, manufacturing, and controls, as well as nonclinical and clinical data packages for RC220, the filing added.The company said the approval enables patient recruitment at four sites in South Korea, with local ethics approval received.The company's shares rose 8% in recent Wednesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7095":"多种金属与采矿","RAC.AU":"RACE ONCOLOGY LTD","IND.AU":"Industrial Minerals Ltd","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Race Oncology在韩国获得癌症候选药物IND批准；股价上涨8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":1,"IND.AU":1},"content_text":"Race Oncology (ASX:RAC) said South Korea's Ministry of Food and Drug Safety (MFDS) approved the investigational new drug application (IND) to evaluate the safety, tolerability, and pharmacokinetics of the company's cancer drug candidate RC220 in combination with doxorubicin in solid tumor patients, subject to minor updates of the trial protocol, according to a Wednesday Australian bourse filing.The approval has been granted following a review of the chemistry, manufacturing, and controls, as well as nonclinical and clinical data packages for RC220, the filing added.The company said the approval enables patient recruitment at four sites in South Korea, with local ethics approval received.The company's shares rose 8% in recent Wednesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}